Phase 1Data readout

MRT-8102

Inflammatory disease

GLUEMonte Rosa Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: MRT-8102
Development stage: Phase 1
Event type: Data readout
Indication: Inflammatory disease

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for MRT-8102 in Inflammatory disease. The expected timing is based on the latest available company guidance and may change.

Development notes

3/20/25- IND submission in H1 2025. 6/10/25- Announces FDA clearance of IND application. 7/21/25- First patient dosed. 11/6/25- Initial data from CVD-risk cohort in H1 2026. 12/16/25:- Present interim Ph1 data in early 2026. Dosing initiated in Part 3 CVD-risk cohort. 01/06/26:- Webcast Jan 7, 2026 to present interim Ph1 MRT-8102 data, including Part 3 CRP CVD-risk cohort. 03/17/26:- Positive interim Ph1 GFORCE-1 data and favorable safety. Expanded GFORCE-1 readout and multiple Ph2 initiations from H2 2026. 05/07/26:- H2 2026 GFORCE-1 readout reiterated. Plan Ph2 GFORCE-2, gout, and hidradenitis suppurativa studies through H1 2027. 08/06/26:- GFORCE-1 dosing complete; readout H2 2026. GFORCE-2 H2 2026, GEMINI-1 Q4 2026/Q1 2027, GALAXY-1 H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 1 data readout for MRT-8102 in Inflammatory disease. The expected timing is based on the latest available company guidance and may change.